Compare Neurocrine Biosciences Inc (NBIX) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Xcel Energy Inc — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while Xcel Energy Inc trades at $73.78 (market cap $45.82B). The key difference: Xcel Energy Inc is far larger — about 3.2× Neurocrine Biosciences Inc's market cap, and Xcel Energy Inc pays a 3.23% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Xcel Energy Inc for 61 Days on average.
| NBIX | XEL | |
|---|---|---|
Market Cap | $14.36B | $45.82B |
Volume | 1,237,180 | 6,910,516 |
Sector | Health | Utilities |
52-Week High | $185.50 | $83.91 |
52-Week Low | $123.10 | $69.39 |
Typical Hold Time | 23 Days | 61 Days |
Enterprise Value | $14.37B | $84.14B |
Dividend Yield | — | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $142.44, down 0.72% with bearish technical signals but strong fundamentals including three consecutive quarterly EPS beats. The company shows robust profitability with 20.91% net margin and 22.09% ROE, supported by growing revenue from $2.9B to $3.4B projected. Recent news highlights pipeline development and conference participation.
Wall Street maintains strong bullish sentiment with 86% buy ratings and $204.18 consensus target, representing 43% upside. Key risks include INGREZZA pricing pressure in 2029 and execution challenges as the company diversifies beyond its main product. The stock offers growth potential but faces near-term technical headwinds.
Xcel Energy (XEL) trades at $73.36, up 1.3% with bullish technical signals and strong institutional support. The stock shows solid fundamentals with $14.67B revenue, 15.28% net margin, and consistent earnings beats. Recent news highlights growth from data center power demand and a $60B capital investment plan. Technical indicators show bullish momentum with support at $72-73 and resistance at $74-75 levels.
XEL presents a compelling investment case with analyst consensus target of $90.83 (24% upside) and 63% buy ratings. Key opportunities include infrastructure expansion and rising power demand, while risks involve wildfire liabilities and high capital expenditure. The stock's valuation at 20.1 P/E appears reasonable given growth prospects and dividend stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
